Visualitzant Vall d'Hebron Barcelona Hospital Campus - VH per títol
Ara mostrant els elements 2846-2865 d 3559
-
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
(Nature Research, 2022-06-09) -
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
(American Society of Clinical Oncology, 2022-10-10) -
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
(Breast Cancer Research Foundation, 2022-08-29) -
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
(BMJ Publishing Group, 2021-03-09) -
Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)
(American Society for Microbiology, 2022-02-16) -
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
(American Society of Clinical Oncology, 2019-11-01) -
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
(American Society of Hematology, 2022-08-23)